PACIRA BIOSCIENCES, INC. Business Combination, Acquisition Related Costs
PACIRA BIOSCIENCES, INC. (PCRX) reported Business Combination, Acquisition Related Costs of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:BusinessCombinationAcquisitionRelatedCosts · last filed 2026-08-04
- PACIRA BIOSCIENCES, INC. business combination, acquisition related costs for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- PACIRA BIOSCIENCES, INC. business combination, acquisition related costs for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- PACIRA BIOSCIENCES, INC. business combination, acquisition related costs for the quarter ending 2025-12-31 was $673.00K, a 12.94% decline year-over-year.
- PACIRA BIOSCIENCES, INC. business combination, acquisition related costs for the quarter ending 2025-09-30 was -$280.00K, a 198.25% decline year-over-year.
- PACIRA BIOSCIENCES, INC. business combination, acquisition related costs for fiscal 2025 was $2.90M, a 98.02% increase from fiscal 2024.
- PACIRA BIOSCIENCES, INC. business combination, acquisition related costs for fiscal 2024 was $1.46M, a 25.52% decline from fiscal 2023.
- PACIRA BIOSCIENCES, INC. business combination, acquisition related costs for fiscal 2023 was $1.96M.
| Period end | Business Combination, Acquisition Related Costs 3 month | Business Combination, Acquisition Related Costs 6 month | Business Combination, Acquisition Related Costs 9 month | Business Combination, Acquisition Related Costs 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-04 | $0.00 10-Q · filed 2026-08-04 | $673.00K derived: sum of 3 quarters · filed 2026-08-04 | $393.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $0.00 10-Q · filed 2026-04-30 | $673.00K derived: sum of 2 quarters · filed 2026-04-30 | $393.00K derived: sum of 3 quarters · filed 2026-04-30 | $1.38M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $673.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $393.00K derived: sum of 2 quarters · filed 2026-02-26 | $1.38M derived: sum of 3 quarters · filed 2026-08-04 | $2.90M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$280.00K 10-Q · filed 2025-11-06 | $711.00K derived: sum of 2 quarters · filed 2026-08-04 | $2.22M 10-Q · filed 2025-11-06 | $3.00M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $991.00K 10-Q · filed 2026-08-04 | $2.50M 10-Q · filed 2026-08-04 | $3.27M derived: sum of 3 quarters · filed 2026-08-04 | $3.56M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $1.51M 10-Q · filed 2026-04-30 | $2.28M derived: sum of 2 quarters · filed 2026-04-30 | $2.57M derived: sum of 3 quarters · filed 2026-04-30 | $2.80M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $773.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.06M derived: sum of 2 quarters · filed 2026-02-26 | $1.29M derived: sum of 3 quarters · filed 2026-02-26 | $1.46M 10-K · filed 2026-02-26 |
| 2024-09-30 | $285.00K 10-Q · filed 2025-11-06 | $515.00K derived: sum of 2 quarters · filed 2025-11-06 | $689.00K 10-Q · filed 2025-11-06 | $1.06M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $230.00K 10-Q · filed 2025-08-05 | $404.00K 10-Q · filed 2025-08-05 | $779.00K derived: sum of 3 quarters · filed 2026-02-26 | $1.17M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $174.00K 10-Q · filed 2025-05-08 | $549.00K derived: sum of 2 quarters · filed 2026-02-26 | $939.00K derived: sum of 3 quarters · filed 2026-02-26 | $1.65M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $375.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $765.00K derived: sum of 2 quarters · filed 2026-02-26 | $1.47M derived: sum of 3 quarters · filed 2026-02-26 | $1.96M 10-K · filed 2026-02-26 |
| 2023-09-30 | $390.00K 10-Q · filed 2024-11-06 | $1.10M derived: sum of 2 quarters · filed 2024-11-06 | $1.59M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $709.00K 10-Q · filed 2024-07-30 | $1.20M 10-Q · filed 2024-07-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |